Exocrine pancreatic insufficiency (EPI), a condition that leads to malnutrition and digestive symptoms, is common among people with cystic fibrosis (CF). Pancreatic enzyme replacement therapy (PERT) is a standard treatment for EPI, but current PERT therapies require taking large doses of medication and do not address all nutrient malabsorption in the digestive tract. Researchers want to know if an investigational oral treatment called ANG003 is safe and to evaluate its effects on nutrient absorption.
During study visits, participants will receive a physical exam and complete questionnaires about their bowel habits and digestion symptoms. On the second and fourth study visits, patients will be asked to eat prepared meals and complete a nutrient absorbance test and have multiple blood samples taken.